Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005520
Status:
COMPLETED
Last Update Posted:
2013-01-17
First Post:
2000-05-25
Brief Title:
Genetic Epidemiology of Responses to Antihypertensives
Sponsor:
Mayo Clinic
Organization:
Mayo Clinic
Study Overview
Official Title:
Genetic Epidemiology of Responses to Antihypertensives
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GERA
Brief Summary:
To determine whether measured variation in genes coding for components of vasoconstriction and volume regulating systems predict interindividual differences in blood pressure response to therapy with a thiazide diuretic hydrochlorothiazide or an angiotensin II receptor blocker candesartan in hypertensive African-Americans N300 treated with each drug and in hypertensive European Americans N300 treated with each drug
Detailed Description:
BACKGROUND
Essential hypertension is a common disorder that contributes to morbidity mortality and cost of health care especially among African-Americans Although a single-drug therapy is commonly prescribed for treatment of hypertension blood pressure levels are controlled in some individuals but not in others The study has the potential to identify genes contributing to the etiology of interindividual differences in blood pressure response to diuretic therapy in African-Americans and European Americans
DESIGN NARRATIVE
Hypertensive adults were treated with the diuretic hydrochlorothiazide 25 mgday for four weeks or with the angiotensin II receptor blocker candesartan 16 mgday for 2 weeks followed by 32 mgday for 4 weeks Interindividual variations in blood pressure responses and in candidate genes coding for components of systems regulating vasoconstriction and volume were measured In addition a panel of 500000 single nucleotide polymorphisms genome-wide was measured in subsets of the most extreme responders and nonresponders to each drug for genome-wide association of analyses
Essential hypertension is a common disorder that contributes to morbidity mortality and cost of health care especially among African-Americans Although a single-drug therapy is commonly prescribed for treatment of hypertension blood pressure levels are controlled in some individuals but not in others The study has the potential to identify genes contributing to the etiology of interindividual differences in blood pressure response to diuretic therapy in African-Americans and European Americans
DESIGN NARRATIVE
Hypertensive adults were treated with the diuretic hydrochlorothiazide 25 mgday for four weeks or with the angiotensin II receptor blocker candesartan 16 mgday for 2 weeks followed by 32 mgday for 4 weeks Interindividual variations in blood pressure responses and in candidate genes coding for components of systems regulating vasoconstriction and volume were measured In addition a panel of 500000 single nucleotide polymorphisms genome-wide was measured in subsets of the most extreme responders and nonresponders to each drug for genome-wide association of analyses
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01HL074735 | NIH | None | httpsreporternihgovquickSearchR01HL074735 |
| R01HL053330 | NIH | None | None |